FDA Approves First Factor XIa Inhibitor for Secondary Stroke Prevention
TUESDAY, Nov. 17, 2026-- The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic...
Read more »